Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Cathepsin V (CTSV) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTSV ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CTSV Products |
| Gene Delivery | CTSV Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based cleavage assays. |
View CTSV Products |
| Benchmark Ab | Anti-CTSV Recombinant Antibody Recombinant positive control matching reference sequence for assay validation. |
View CTSV Products |
| Validator | CTSV siRNA Set For knockdown verification in target specificity assays. |
View CTSV Products |
| Related Target A | CTSL (Cathepsin L) Highly homologous family member (80% identity) required for counter-screening to ensure off-target safety. |
View CTSL Products |
| Related Target B | CTSK (Cathepsin K) Lysosomal cysteine protease involved in bone resorption; crucial for selectivity profiling. |
View CTSK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Highly Homologous Off-Target Cross-Reactivity (CTSL/CTSK) | Human/Mouse/Cyno ortholog proteins and homolog panels (CTSL, CTSK, CTSS) available with >95% purity verified by SDS-PAGE. |
| Conformation-Sensitive Inhibitor Screening | Lentivirus-mediated stable cell lines preserve native lysosomal localization and post-translational processing. |
| Lack of Controls | Clinical-grade benchmark antibodies included as reference controls. |
| False Positives in Small Molecule Screens | Sequence-verified siRNA sets included for functional knockdown validation. |
Live CTSV R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Cathepsin V (CTSV) therapeutics is intensifying, with major players shifting focus from non-selective cathepsin inhibitors to highly selective small molecules and monoclonal antibodies. As first-generation broad-spectrum inhibitors faced clinical setbacks due to off-target toxicities (principally related to CTSL and CTSK inhibition), the next wave of R&D is targeting CTSV-specific structural pockets. Key therapeutic areas include metastatic breast cancer, colorectal cancer, and corneal disorders where CTSV is selectively upregulated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Solid Tumors (Breast, Colon), Corneal Disease | Selectivity Assay (Need high-purity CTSV vs. CTSL/CTSK proteins) |
| Monoclonal Antibodies | Biopharma Innovators | Metastatic Cancers, Thymic Disorders | Epitope Mapping (Need native HEK293-expressed CTSV antigens) |
| siRNA / RNAi Therapeutics | RNAi Specialists | Hyperproliferative Skin Diseases | In vitro Knockdown Validation (Need sequence-verified siRNA sets) |